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Abstract. The cardiovascular drug lacidipine was screened in
vitro for possible antibacterial activity with respect to 389 Gram-
positive and Gram-negative bacterial strains. It was noticed that
most bacteria (233) failed to grow at 50-200 Ìg/mL
concentrations of the drug. Some strains were inhibited at even
lower concentrations. The bacteria could be arranged according
to their decreasing order of sensitivity as follows: Staphylococcus
aureus, Vibrio cholerae, Salmonella spp., Shigellae, Escherichia
coli, Bacillus spp., Klebsiellae and Pseudomonas spp. Lacidipine
was found to be bacteriostatic in nature against S. aureus and V.
cholerae. When administered to Swiss strain of white mice at
doses of 30 and 60 Ìg/mouse, lacidipine significantly protected
the animals challenged with 50 MLD of S. typhimurium NCTC
74. According to the chi-square test, the in vivo data were highly
significant (p<0.001).
The multifunctional nature of most medicinal agents has
proved more to be the rule rather than the exception.
Understanding this concept allowed scientists to investigate
the antimicrobial properties of many drugs not pharmaco-
logically classified as antimicrobial. Positive results were
obtained for many drugs falling almost invariably under one
of the following groups, namely psychotropics, neuroleptics,
local anaesthetics, antihypertensives, antihistaminics, cardio-
vascular and antiinflammatory agents. Notable amongst them
are the psychotropic chlorpromazine (1), the antihistamines
bromodiphenhydramine and diphenhydramine (2), methdilazine
(3), promethazine (4) and trimeprazine (5), the tranquilizer
promazine (6), the antihypertensives propranolol (7) and
methyl-DOPA (8), the local anesthetics procaine and
lignocaine (9), the antiinflammatory agent diclofenac (10, 11),
the neuroleptic phenothiazines trifluoperazine (12) and
fluphenazine (13), the cardiovascular agent amlodipine and
oxyfedrine (14, 15), and the antispasmodic compound
dicyclomine (16). All these agents showing antimicrobial
function were grouped together and termed as "non-
antibiotics" (17). Here we screened the cardiovascular drug
lacidipine for its antibacterial activity.
Materials and Methods
Bacteria. A total of 389 bacterial isolates belonging to 16 genera
comprising 115 Gram-positive and 274 Gram-negative types were
tested. Several strains were obtained from the NCTC and ATCC. The
rest were human isolates, identified by the method of Collee et al.
(18) and were preserved in a freeze-dried state. 
Drugs. The cardiovascular drug lacidipine (Figure 1) was obtained in
pure dry powder form from Sun Pharmaceuticals, India and was
preserved at 4ÆC. 
Media. Liquid media used for this study were peptone water (PW
(Sigma, St. Louis, USA); Oxoid brand bacteriological peptone 1%
(w/v) plus Analar NaCl 0.5% (w/v)(Oxoid, Basingstoke UK), nutrient
broth (NB, Oxoid) and Mueller Hinton broth (MHB; Oxoid). Solid
media were peptone agar (PA), nutrient agar (NA) and Mueller
Hinton agar (MHA), obtained by solidifying the respective liquid
media with 1.2% (w/v) agar (Oxoid No.3); another solid medium used
was desoxycholate citrate agar (DCA, Oxoid). The pH was
maintained at 7.2-7.4 for all the media. NA was used for tests with
Gram-positive bacteria and PA and DCA were used for the
remaining bacteria as needed.
Determination of minimum inhibitory concentration (MIC) of
lacidipine. Lacidipine was added at concentrations of 0 (control), 10,
25, 50, 100 and 200 Ìg/mL in molten NA and poured into Petri-dishes
according to NCCLS (19). The organisms were grown in NB or PW
for 18 h and harvested during the stationary growth phase. A direct
suspension of the organisms was prepared in 5 mL sterile distilled
water. The turbidity of the suspension was adjusted to match a 0.5
McFarland’s standard (20) with a spectrophotometer (Chemito UV
847
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2600 Double Beam UV-VIS Spectrophotometer (Mumbai, India)) at
625 nm, which corresponded to 2.4x108 colony forming units
(cfu)/mL. The inocula were prepared by further diluting the
suspension 1:100 with sterile distilled water such that a 2 mm
diameter loopful of a culture contained 105 cfu. These were spot-
inoculated onto the NA plates containing increasing amounts of the
drug, including a control. The plates were incubated at 37ÆC,
examined after 24 h and incubated further for 72 h, where necessary.
The lowest concentration of the drug in a plate that failed to show
any visible macroscopic growth was considered as its MIC. The MIC
(MIC 50 and MIC 90) determination was performed in triplicate for
each organism and the experiment was repeated where necessary. 
Mechanism of antibacterial action of lacidipine. The MIC of
lacidipine against S. aureus NCTC 6571 and V. cholerae 1347 were
found to be 25 Ìg/mL. At the logarithmic growth phase of the
cultures, the cfu counts of the strains were taken and twice the MIC
of lacidipine (50 Ìg/mL) was added to each culture. Subsequently,
the cfu counts of the cultures were determined after 2, 4, 6 and 18
h after adding the drug. 
In vivo tests. Swiss strain of male white mice weighing 20 g each were
used for the in vivo studies. Animals were maintained at standard
conditions of 21±1ÆC and 50-60% relative humidity with a
photoperiod of 14:10 h light:dark. Water and a dry pellet diet were
given ad libitum. The virulence of the test strain S. typhimurium NCTC
74 was determined by repeated mouse passage and the median lethal
dose (MLD or LD50) of the passaged strain corresponding to 1.85x109
cfu/mouse suspended in 0.5 mL NB served as the challenge dose (21)
for all the groups of animals. Reproducibility of the challenge dose
was ensured by standardization of its optical density in a Klett-
Summerson colorimeter (Lorton, VA, USA) at 640 nm. To determine
the toxicity of lacidipine, 30 mice were taken, 10 of which were
injected with 60 Ìg of the drug, 10 received 30 Ìg and the remaining
mice received 15 Ìg of the drug. They were kept under observation up
to 100 h. Three groups of mice, 20 animals/group, were kept in
separate cages. Group I was intraperitoneally administered 15 Ìg
lacidipine per mouse, Group II was given 30 Ìg and Group III
received 60 Ìg of the drug per mouse. After 3 h, each group was
challenged with 50 MLD of S. typhimurium NCTC 74. A control group
of 60 mice was also injected similarly with the same bacterial strain
and 0.1 mL sterile saline instead of lacidipine. The protective capacity
of the drug was determined by recording the mortality of the mice in
different groups up to 100 h of the treatment and statistically using
the ¯2 test. In another experiment, 4 groups of mice, 5 animals/group,
were taken. Groups 1 and 3 were administered 60 Ìg of lacidipine,
while groups 2 and 4 were given 0.1 ml sterile saline. After 3 h, all the
groups were given a 50 MLD challenge of S. typhimurium NCTC 74.
After 2 h, Groups 1 and 2 were sacrificed. Their heart blood was
collected and their livers and spleens were removed aseptically and
homogenised in tissue homogenisers. The cfu counts of the individual
organs were determined separately. The same procedure was applied
to Groups 3 and 4, 18 h after the challenge. Statistical analysis of the
in vivo data was performed using Student's t-test. 
Results
Antibacterial activity of lacidipine by in vitro screening. Among
389 bacterial strains tested, it was found that Gram-positive
organisms and vibrios were more sensitive to lacidipine than
others used in this study. Interestingly, Pseudomonas aeruginosa,
which is usually resistant to a large number of antibiotics and
non-antibiotics, was sensitive towards this drug (Table I). 
Bacteriostatic action of lacidipine. At the logarithmic growth
phase of the culture of S. aureus NCTC 6571, the cfu count of
the strain was 2x108. Subsequently, the cfu was 8.0x105 after
2 h, 5.2x104 after 4 h, 9.6x102 after 6 h and 4.0x102 at the end
of 18 h (Figure 2). A similar bacteriostatic action was recorded
in V. cholerae 1347 (Figure 2). 
In vivo tests. Table II shows that in the control group, 49 out of
60 animals died within 100 h of the challenge and no mortality
was recorded in those groups of mice that received different
doses of lacidipine alone, which was totally non-toxic. There
was a significant protection in the drug-treated groups. In
Table III, it can be seen that lacidipine significantly reduced
the number of viable bacteria in heart blood, liver and spleen
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Figure 1. Structure of lacidipine.
Figure 2. Effect of lacidipine on Gram-positive and Gram-negative
bacteria.
of mice, both at 2 h and 18 h after challenge, when compared
to the control (saline-treated) mice. Statistical analysis showed
p<0.05 for 2 h samples and p<0.01 for 18 h samples.
Discussion
Lacidipine was found to possess powerful antibacterial activity
both in vitro and in vivo. While sensitive bacterial strains
occurred among Staphylococcus, Bacillus, Vibrio spp. and some
enterobacteria, lacidipine was less active on strains of Shigella,
Salmonella, E. coli and Klebsiella. It may be pointed out here
that lacidipine demonstrated a pronounced inhibitory action
against Pseudomonas aeruginosa, an organism which is known
to be multidrug resistant. Lacidipine was bacteriostatic in vitro
against both Gram-positive and Gram-negative bacteria. The
protection offered by lacidipine in mice challenged with a
virulent bacterium was found to be statistically highly
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Table I. In vitro activity of lacidipine on Gram-positive and Gram-negative bacteria.
Bacteria No. No. of strains inhibited by lacidipine (Ìg/mL)
Tested 10 25 50 100 200 >200
Bacillus spp. 10 4 1 2 1 1 1
Corynebacterium diphtheriae 1 1
Staphylococcus aureus 105 18 34 34 17 2
Escherichia coli 35 6 10 9 10
Salmonella spp. 17 3 4 4 6
Shigella spp. 44 8 24 8 2 2
Klebsiella spp. 9 2 1 6
Hafnia spp. 1 1
Proteus spp. 7 3 4
Providencia spp. 1 1
Citrobacter spp. 1 1
Arizona spp. 1 1
Pseudomonas aeruginosa 10 2 3 1 2 2
Pseudomonas putida 2 1 1
Bordetella bronchiseptica 1 1
Pasturella septica 136 1 1
Vibrio cholerae 110 22 24 19 25 20
V. parahaemolyticus 33 3 10 9 9 2
Total 389 56 74 107 78 48 26
Table II. Determination of the protective capacity of lacidipine in vivo.
Control group* Test group*
Mouse deaths Lacidipine (Ìg) Mouse deaths
(out of 60) injected per mouse (out of 20)
0.1 mL sterile saline 49 15 12
30 8
60 0
*Received a challenge dose of 1.85x109 cfu of S. typhimurium NCTC
74 in 0.5 mL NB. None of the animals died when 15 Ìg, 30 Ìg or 60 Ìg
lacidipine was injected into 3 separate groups of mice (20 mice in
each), i.e. lacidipine was found to be totally non-toxic to mice. p<0.001,
acccording to the Chi-square test.
Table III. Reduction in cfu/mL of S. typhimurium NCTC 74 in organ
homogenates of mice treated with lacidipine.
Time of Group Mouse Lacidipine Cfu/mL counts in 
sampling No. /mouse
Heart blood Liver Spleen
2 h I 1 60 Ìg 2.1x103 1.1x103 4.3x103
2 2.3x103 3.0x103 4.6x103
3 2.5x103 6.5x104 1.2x103
4 3.1x104 2.1x103 6.2x103
5 5.6x103 1.2x104 2.5x104
2 h II 1 None 5.7x106 2.8x106 8.4x106
2 saline 4.0x105 4.6x106 1.2x105
3 (Control) 5.8x105 6.0x106 5.4x106
4 6.9x106 7.0x106 8.6x105
5 7.8x106 8.5x106 8.8x106
18 h III 1 60 Ìg 3.6x104 5.8x103 7.8x105
2 2.6x103 7.3x104 3.5x105
3 4.5x104 3.8x104 7.2x106
4 1.1x103 2.3x104 4.0x104
5 7.0x103 7.1x104 3.4x104
18 h IV 1 None 4.7x108 5.8x108 5.0x108
2 saline 5.4x108 5.2x108 5.4x109
3 (Control) 6.8x107 2.7x107 8.2x108
4 5.6x108 3.9x107 4.9x107
5 7.2x109 8.0x108 1.8x107
Viable counts between two groups significantly differ at: p<0.05 for 
2 h samples and p<0.01 for 18 h samples, respectively.
significant. Lacidipine is a widely used third-generation
calcium channel blocker, which has both long-lasting
antihypertensive activity and also antioxidant properties (22).
This class of pharmaceutical agents relaxes smooth muscle
and dilates coronary and peripheral arteries. Lacidipine has
more influence on vessels and less on the myocardium and has
no anti-arrhythmic activity. It rarely precipitates heart failure
because any negative inotropic effect is often offset by a
reduction in left ventricular work. The dose initially is 4 mg
daily but may be increased to 6 mg, if necessary, after 3-4
weeks. In our study, we observed that successful protection of
mice could be obtained when the amount of lacidipine was
either 30 mg or 60 mg/animal. Looking at the low dose of
lacidipine as applied to human beings for cardiovascular
ailments, our dose as an antimicrobial drug may appear to be
rather high. However, it may be mentioned here that the drug
was totally non-toxic for the animals, even at the highest dose
used, since all the mice survived not only for 100 h as
presented here (Table II), but also up to 7 days. This again
proves that lacidipine is a non-toxic agent. Moreover, in our
present study, lacidipine was administered only once, whereas
lacidipine is prescribed as a cardiovascular drug for a patient
who may take lacidipine for a considerable time and even for
their whole life. The present study indicates the potential of
lacidipine as a noteworthy antimicrobial agent, because such
properties are likely to improve its usage in humans.
Furthermore, the antimicrobial efficiency of lacidipine may be
enhanced by structural modifications or be augmented by
suitably combining lacidipine with conventional antimicrobial
agents to produce synergism. 
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